What is HC Wainwright’s Estimate for SABS FY2024 Earnings?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Equities research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of SAB Biotherapeutics in a report issued on Thursday, November 7th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($3.75) for the year, down from their prior estimate of ($3.64). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.64) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2024 earnings at ($1.30) EPS, FY2025 earnings at ($5.27) EPS and FY2026 earnings at ($4.01) EPS.

SABS has been the subject of a number of other research reports. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price objective for the company. Oppenheimer restated an “outperform” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $3.42 on Monday. SAB Biotherapeutics has a 1-year low of $2.16 and a 1-year high of $9.72. The company has a quick ratio of 5.24, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average of $2.91 and a two-hundred day moving average of $2.99.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

Hedge Funds Weigh In On SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. First PREMIER Bank acquired a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned approximately 0.21% of SAB Biotherapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.